NCT02330237

Brief Summary

The aim of the study is to evaluate the safety and the therapeutic activity of the combination of Natural Gel combination and hair mask of plant origin in patients with mild to moderate plaque psoriasis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Jan 2015

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 30, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 1, 2015

Completed
Same day until next milestone

Study Start

First participant enrolled

January 1, 2015

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2016

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2017

Completed
Last Updated

July 23, 2018

Status Verified

July 1, 2018

Enrollment Period

1.8 years

First QC Date

December 30, 2014

Last Update Submit

July 19, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Modified Psoriasis Assessment severity index

    up to 16 weeks

Study Arms (2)

patients

ACTIVE COMPARATOR

natural gels

Drug: natural gels

subjects

PLACEBO COMPARATOR

These patients will receive that placebo (vehicle) products.

Drug: Placebo

Interventions

whole fruits and vegetables

Also known as: plant origin
patients
subjects

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects with stable (for at least 6 months), mild to moderate (less than 10% of the skin surface area) plaque psoriasis.
  • Male and female ≥ 18 years old.
  • Subject is capable of giving a written informed consent.

You may not qualify if:

  • Subjects treated by topical or photo or systemic anti psoriatic therapy during 4 weeks prior to the study.
  • Subjects treated with Biological products for psoriasis for the last 3 months prior to starting the present study.
  • Subjects with any other type of psoriasis but vulgaris (plaque ).
  • Use of investigational agents \< 30 days prior to the study.
  • Low compliance.
  • Subjects who are mentally or physically unable to comply with all aspects of the study.
  • Pregnant women.
  • Known allergic reaction to fragrance or any ingredient of the test products.
  • Other inflammatory skin disease in the treatment area that may confound the evaluation of the psoriasis.
  • A medical condition that may put the patient at a general risk and therefore would prevent participation in the clinical trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chaim Sheba Med. center. Dept. Of Dermatology

Reamat- Gan, Ramat-almogi, 34793, Israel

Location

MeSH Terms

Conditions

Parapsoriasis

Condition Hierarchy (Ancestors)

Skin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Felix Pavlotzky, MD

    Chaim sheba Medical Center, Dept. of Dermatolgy. Tel-Hashomer, Israel

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 30, 2014

First Posted

January 1, 2015

Study Start

January 1, 2015

Primary Completion

November 1, 2016

Study Completion

September 1, 2017

Last Updated

July 23, 2018

Record last verified: 2018-07

Locations